The effect of piribedil on l-DOPA-induced dyskinesias in a rat model of Parkinson's disease: Differential role of α2 adrenergic mechanisms

Journal of Neural Transmission

Volumn 120, Issue 1, 2013, Pages 31-36

  Gerlach, Manfred ^a   Halley, Paul ^b   Riederer, Peter ^a   Van Den Buuse, Maarten ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

2 Adrenergic receptors; 6 Hydroxydopamine; Dopamine agonists; Hemiparkinsonian rat; Levodopa; Parkinson therapy

Indexed keywords

BENSERAZIDE; CLONIDINE; IDAZOXAN; LEVODOPA; PIRIBEDIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DYSKINESIA; DYSTONIA; FORELIMB DYSKINESIA; LOCOMOTIVE DYSKINESIA; NEUROTRANSMISSION; NONHUMAN; OROLINGUAL DYSKINESIA; PARKINSON DISEASE; PREMEDICATION; PRIORITY JOURNAL; RAT;

ADRENERGIC AGENTS; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ANIMALS; ANTIPARKINSON AGENTS; BENSERAZIDE; CLONIDINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; DYSTONIA; FACIAL ASYMMETRY; IDAZOXAN; LEVODOPA; LOCOMOTION; OXIDOPAMINE; PARKINSON DISEASE; PIRIBEDIL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2; STATISTICS, NONPARAMETRIC; UPPER EXTREMITY;

EID: 84872338067     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0818-7     Document Type: Article

References (37)

1. Bardgett ME, Points M, Ramsey-Faulkner C, Topmiller J, Roflow J, McDaniel T, Lamontagne T, Griffith MS (2008) The effects of clonidine on discrete-trial delayed spatial alternation in two rat models of memory loss. Neuropsychopharmacology 33:1980-1991 (Pubitemid 351832596)
2. Brotchie JM, Lee J, Venderova K (2005) Levodopa-induced dyskinesia in Parkinson's disease. J Neural Transm 112:359-391 (Pubitemid 40868050)
3. Carey RJ (1986) Relationship of changes in spontaneous motor activity to spontaneous circling in rats with unilateral 6-hydroxydopamine lesions of the substantia nigra. Exp Neurol 92:591-600 (Pubitemid 16074638)
4. Cenci MA, Lee CS, Bjorklund A (1998) l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694-2706 (Pubitemid 28362576)
5. Cooper DR, Marrel C, Testa B, van de Waterbeemd H, Quinn N, Jenner P, Marsden CD (1984) l-DOPA methyl ester - a candidate for chronic systemic delivery of l-DOPA in Parkinson's disease. Clin Neuropharmacol 7:89-98 (Pubitemid 14138570)
6. Corrodi H, Farnebo LO, Fuxe K, Hamberger B, Ungerstedt U (1972) ET495 and brain catecholamine mechanisms: evidence for stimulation of dopamine receptors. Eur J Pharmacol 20:195-204
7. Creese I (1974) Behavioural evidence of dopamine receptor stimulation by piribedil (ET495) and its metabolite S584. Eur J Pharmacol 28:55-58
8. Dekundy A, Lundblad M, Danysz W, Cenci MA (2007) Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179:76-89 (Pubitemid 46441485)
9. 1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res 1158:135-143 (Pubitemid 47068412)
10. Fox SH, Henry B, Hill MP, Peggs D. Crossman AR, Brotchie JM (2001) Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan. Mov Disord 16:642-650 (Pubitemid 36040843)
11. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987-1041 (Pubitemid 26383833)
12. Gerlach M, van den Buuse M, Blaha C, Bremen D, Riederer P (2004) Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat. Naunyn Schmiedebergs Arch Pharmacol 370:388-394 (Pubitemid 40022459)
13. Gerlach M, Riederer P, Scheller D (2011) Editorial. Mechanisms underlying and medical management of l-Dopa-associated motor complications. J Neural Transm 118:1659-1660
14. Grondin R, Hadj Tahar A, Doan VD, Ladure P, Bedard PJ (2000) Noradrenoceptor antagonism with idazoxan improves l-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch Pharmacol 361:181-186 (Pubitemid 30062450)
15. Halley P, Riederer P, van den Buuse M, Lohmueller K, Gerlach M (2010) Anti-dyskinetic effects of piribedil on levodopa-induced dyskinesia in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Mov Disord 25 (Suppl S2):S209-S209
16. Henry B, Crossman AR, Brotchie JM (1999a) Effect of repeated l-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp Neurol 155:204-220 (Pubitemid 29124714)
17. 2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of l-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 14:744-753 (Pubitemid 29509616)
18. Herradon G, Morales L, Gramage E, Alguacil LF (2008) Comparative study of alpha2-adrenoceptors in Fischer 344 and Lewis rats. Evidence for clonidine-induced place aversion. Life Sci 82:1186-1190
19. Iravani MM, Jenner P (2011) Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm 118:1661-1690
20. Lane EL, Dunnett SB (2010) Pre-treatment with dopamine agonists influence l-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat. Behav Brain Res 213:66-72
21. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15:120-132 (Pubitemid 35478015)
22. Lundblad M, Picconi B, Lindgren H, Cenci MA (2004) A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16:110-123 (Pubitemid 38569802)
23. Millan MJ (2010) From the cell to the clinic: a comparative review of the partial D-2/D-3 receptor agonist and alpha(2)-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. Pharmacol Therap 128:229-273
24. 2-adrenoceptors: cellular and functional characterization. J Pharmacol Exp Ther 297:876-887 (Pubitemid 32472482)
25. Müller T, Russ H (2006) Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Exp Opin Pharmacother 7:1715-1730
26. Nakagawa M, Ohgoh M, Nishizawa Y, Ogura H (2004) Dopaminergic agonists and muscarinic antagonists improve lateralization in hemiparkinsonian rats in a novel exploratory Y-maze. J Pharmacol Exp Ther 309:737-744 (Pubitemid 38542630)
27. 2-adrenoceptor. J Pharmacol Exp Ther 303:805-814 (Pubitemid 35231257)
28. Paxinos G, Watson C (1986) The rat brain in stereotaxic co-ordinates, 2nd edn. Academic Press, New York
29. Rascol O, Arnulf I, Peyro-Saint Paul H, Brefel-Courbon C, Vidailhet M, Thalamas C, Bonnet AM, Descombes S, Bejjani B, Fabre N, Montastruc JL, Agid Y (2001) Idazoxan, an alpha-2 antagonist, and l-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord 16:708-713 (Pubitemid 36040852)
30. Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A (2006) Early piribedil monotherapy of Parkinson's disease: a planned seven-month report of the REGAIN study. Mov Disord 21:2110-2115 (Pubitemid 46140421)
31. Smith LA, Tel BC, Jackson MJ, Hansar MJ, Braceras R, Bonhomme C, Chezaubernard C, Del Signore S, Rose S, Jenner P (2002) Repeated administration of piribedil induces less dyskinesia than l-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord 17:887-901 (Pubitemid 36040993)
32. Smith LA, Jackson MJ, Johnston L, Kuoppamaki M, Rose S, Al-Barghouthy G, Del Signore S, Jenner P (2006) Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates. Clin Neuropharmacol 29:112-125 (Pubitemid 44503888)
33. Turle-Lorenzo N, Maurin B, Puma C, Chezaubernard C, Morain P, Baunez C, Nieoullon A, Amalric M (2006) The dopamine agonist piribedil with l-DOPA improves attentional dysfunction: relevance for Parkinson's disease. J Pharmacol Exp Ther 319:914-923
34. Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24:485-493
35. Watling K (2006) The Sigma-RBI handbook of receptor classification and signal transduction. Sigma-RBI, Natick
36. Winkler C, Kirik D, Bjorklund A, Cenci MA (2002) l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10:165-186 (Pubitemid 34775470)
37. Ziegler M, Castro-Caldas A, Del Signore S, Rascol O (2003) Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study. Mov Disord 18:418-425 (Pubitemid 36527283)